Cardio-oncology is a medical subspecialty concerned with the diagnosis and treatment of cardiovascular disease (CVD) and organ failure mediated by micro- to macro-circulation defects in cancer patients and survivors. The risk of CVD in cancer survivors is eight times higher than the general population, and the relative risk of coronary artery disease and heart failure (HF) is 10 times and 15 times higher, respectively, compared to their siblings without cancer. It is important to note that cancer treatments including chemotherapy and radiation can lead to both short- (< 1 year) and long-term (> 5 years) cardiovascular complications. Previously, Dr. Edward T.H. Yeh initiated the MD Anderson Practice (MAP) project, and published 16 MAPs to provide the current best practice we considered at UT MD Anderson. As shown in these MAPs, one of the key issues of cardio-oncology practice and science is how we can allow cancer patients to receive maximum and uninterrupted treatments for cancer while protecting them from cancer therapy-mediated cardiovascular complications. Therefore, it is crucial to understand not only pathophysiology of CVD, but also mechanistic insights of how each cancer treatment can control cancer growth and metastasis. Without having the profound knowledge in the pathophysiological, clinical and epidemiologic aspects of cardiovascular complications of existing cancer therapy, it is impossible to establish the strong evidence-based strategies and approaches for both short- and long-term cardiovascular complications after cancer treatment. In addition, we believe that cardio-oncology science should not be restricted to deal with the side effects of each specific cancer drug, because many common cardiovascular phenotypes among the different cancer treatments are also observed. This Research Topic provides a comprehensive overview from both of the current research and practice, and a platform for obtaining the logical and up-to-date treatment and prevention of CVD in cancer patients and survivors.

Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well as for cardio-oncology researchers. - Covers basic science of cardio-oncology to provide readers with the necessary background - Addresses cardiotoxicity related to current cancer therapeutic modalities - Discusses diagnostic and management approaches of patients with underlying cardiac risk factors as well as otherwise healthy cancer patients

Over the last years, thanks to growing advances in the field of cancer therapies, a considerable decrease in cancer mortality has been observed. Unfortunately, such therapies have shown a wide spectrum of cardiotoxicities. This book provides the readers with the latest advances and insights in the ever-expanding field of Cardio-Oncology. Specific topics discussed in the book include the potential role of inflammation in Cardio-Oncology and the description of the different manifestations of cardiotoxicities (including vascular toxicity, systemic hypertension, arrhythmias), analyzing the complex relationships between cancer and heart failure, two conditions whose prevalence increases with ageing. Furthermore, the role of biomarkers and imaging in cardio-oncology is discussed.

This groundbreaking book presents a unique and practical approach to the evolving field of exercise oncology - the study of physical activity in the context of cancer prevention and control. Presenting the current state of the art, the book is sensibly divided into four thematic sections. Following an opening chapter presenting an overview and timeline of exercise oncology, the chapters comprising part I discuss primary cancer prevention, physical activity and survivorship, and the mechanisms by which these operate. Diagnosis and treatment considerations are discussed in part II, including prehabilitation, exercise during surgical recovery, infusion and radiation therapies, and treatment efficacy. Post-treatment and end-of-life care are covered in part III, including cardio-oncology, energetics and palliative care. Part IV presents behavioral, logistical and policy-making considerations, highlighting a multidisciplinary approach to exercise oncology as well as practical matters such as reimbursement and economics. Written and edited by experts in the field, Exercise Oncology will be a go-to practical resource for sports medicine clinicians, family and primary care physicians, oncologists, physical therapy and rehabilitation specialists, and all medical professionals who treat cancer patients.

Cancer and cardiovascular disease (CVD) are the two most common causes of mortality and morbidity worldwide. The incidence of both cancer and cardiovascular disease increases with age. With increased life expectancy, the burden of both these diseases will increase substantially in coming years. Patients with CVD share multiple common risk factors and lifestyle behaviors in addition to frequently suffering from multiple comorbid conditions. Tobacco use, hypertension, high cholesterol, diabetes, physical inactivity, and poor nutrition are all established risk factors of heart disease. Patients with diseases such as breast cancer may develop CVD from treatment, such as use of chemotherapy and RT. Effects on the heart are a potentially significant and serious clinical problem in radiation therapy treatment of breast cancer. Over the course of the past 50 years, there have been great advances in the delivery of RT due to the development of new techniques, beam energy, improvement in imaging modalities, and development of image registration strategies. It is hypothesized that cardiac damage from RT is correlated to the dose absorbed by the heart and differs between left- and right-breast radiotherapy. The damage to cardiac micro- and macro-vasculature is the pathophysiological cause of RT-related heart disease. Given the growing clinical relevance of cardio-oncology, this Frontiers in Oncology Research Topic provides a venue for disseminating focused reviews and cutting edge research in this quickly growing field. We encourage submission of original papers and reviews dealing with cardiac toxicity after breast cancer treatment, motion management to reduce cardiac exposure, imaging to evaluate potential cardiac toxicities and primary prevention of cardiac disease in the breast cancer patient.

This concise and handy manual provides straightforward, up-to-date guidance for cardiologists and other practitioners on the management of cancer patients with cardiac problems, whether they be due to the cancer itself or to antineoplastic treatment. Detailed attention is devoted to the various forms of cardiotoxicity associated with chemotherapy and radiotherapy. The drugs commonly responsible for each toxicity are identified and clear advice is offered on monitoring techniques and treatment approaches. In addition, the issue of cardiotoxicity due to cancer treatment in particular patient groups – children, the elderly, and those with pre-existing cardiac disease – is addressed separately, with guidance on when and how antineoplastic (and/or cardiological) treatments should be modified. Further sections describe the correct responses to cardiac problems secondary to the cancer itself, including thromboembolic disorders and electrolyte imbalances, and the diagnosis, treatment, and follow-up of cardiac tumors. A closing section considers how to improve cooperation between oncologists, cardiologists, and general practitioners to ensure that cancer patients’ cardiovascular needs are met in a multidisciplinary approach.

Clinical Cardio-oncology is a comprehensive, clinically focused title for cardiologists, oncologists, and specialists in cardio-oncology programs who need up-to-date knowledge about the cardiovascular effects of cancer treatment, especially on long-term cancer survivors. This brand-new resource covers the implementation of cardio-oncology into your practice, while a strong focus on patient management offers helpful information on coordinating care before, during, and after therapy. Its highly organized four-section format allows readers to quickly and easily locate relevant information. - Comprised of four sections for quick and easy reference: Oncology and Hematology Principles; Cardiac Complications from Cancer Therapy; Coordination of Care; and Cardio-oncology in Practice. - Provides expert wisdom from cardio-oncology authorities around the world, as well as consultation and perspectives from pioneers in the field of oncology. - Highlights the principles of cancer therapies, including radiation and tumor therapy, as well as pre-, intra-, and post-therapy cardiology evaluation. - Boasts chapters on implementing cardio-oncology into practice: primary cancer centers, comprehensive referral centers, group practices, and educational needs and goals for fellowship programs. - Advises on how to coordinate care for the patient at every stage of treatment (pre-therapy, during therapy, after therapy, and end-of-life). - Presents detailed information on various cardiac complications from cancer therapy, such as cardiomyopathy, vascular disease, arrhythmias, and hypertension. - Teaches the principles of oncology and hematology with coverage of different therapy types and cardiac tumors. - Includes a comprehensive drug guide.